Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.

Bachy, E; Savage, KJ; Huang, HQ; Kwong, YL; Gritti, G; Zhang, QY; Liberati, AM; Cao, J; Yang, HY; Hao, SG; Hu, JD; Zhou, K; Russo, F; Zhang, HL; Sang, W; Ji, J; Liu, H; Huang, S; Zinzani, PL

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索